Company Overview - Hanyu Pharmaceutical Co., Ltd. is located in Longhua District, Shenzhen, Guangdong Province, and was established on April 2, 2003. The company was listed on April 7, 2011. Its main business involves chemical pharmaceuticals and medical devices, with 100% of its revenue coming from the pharmaceutical manufacturing industry [1]. Stock Performance - As of September 3, Hanyu Pharmaceutical's stock price decreased by 2.02%, trading at 26.16 CNY per share, with a total market capitalization of 23.106 billion CNY. The stock has increased by 102.95% year-to-date, with a 0.19% increase over the last five trading days, an 11.79% increase over the last 20 days, and a 53.88% increase over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent appearance on August 4, where it recorded a net purchase of 545 million CNY [1]. Financial Performance - For the first half of 2025, Hanyu Pharmaceutical achieved a revenue of 549 million CNY, representing a year-on-year growth of 114.86%. The net profit attributable to the parent company was 145 million CNY, showing a significant year-on-year increase of 1504.30% [2]. - The company has distributed a total of 417 million CNY in dividends since its A-share listing, with no dividends distributed in the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 9.95% to 63,000, with an average of 11,841 circulating shares per person, a decrease of 3.98% from the previous period [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fifth largest, holding 7.6817 million shares, which is a decrease of 386,400 shares compared to the previous period [3].

Core Viewpoint - Antu Biology's stock price has shown fluctuations, with a slight increase on September 1, 2023, while the company faces a decline in revenue and net profit for the first half of 2025 compared to the previous year [1][2]. Financial Performance - As of June 30, 2025, Antu Biology reported a revenue of 2.06 billion yuan, a year-on-year decrease of 6.65% [2]. - The net profit attributable to shareholders for the same period was 571 million yuan, reflecting a year-on-year decrease of 7.83% [2]. - The company's stock price has decreased by 2.34% year-to-date and by 2.52% over the last five trading days [1]. Shareholder and Institutional Holdings - The number of shareholders increased to 34,200 as of June 30, 2025, with an average of 16,719 shares held per shareholder, a slight decrease of 0.04% [2]. - Among the top ten circulating shareholders, Zhonggeng Value Pioneer Stock holds 9.25 million shares, an increase of 160,200 shares from the previous period [3]. - The Hong Kong Central Clearing Limited increased its holdings by 554,400 shares, while Southern CSI 500 ETF exited the top ten circulating shareholders list [3]. Business Overview - Antu Biology, established on September 15, 1999, specializes in the research, production, and sales of in vitro diagnostic reagents and instruments [1]. - The company's main revenue sources include reagents (86.63%), instruments (10.99%), and other services (1.40%) [1].

Company Overview - Hanyu Pharmaceutical Co., Ltd. is located in Longhua District, Shenzhen, Guangdong Province, and was established on April 2, 2003. The company was listed on April 7, 2011. Its main business involves chemical pharmaceuticals and medical devices, with 100% of its revenue coming from the pharmaceutical manufacturing industry [1]. Stock Performance - As of August 25, Hanyu Pharmaceutical's stock price increased by 2.05%, reaching 28.90 CNY per share, with a trading volume of 2.188 billion CNY and a turnover rate of 10.31%. The total market capitalization is 25.526 billion CNY [1]. - Year-to-date, Hanyu Pharmaceutical's stock price has risen by 124.20%. Over the past five trading days, the stock has decreased by 3.38%, while it has increased by 51.15% over the past 20 days and 102.24% over the past 60 days [1]. Financial Performance - For the first half of 2025, Hanyu Pharmaceutical achieved a revenue of 549 million CNY, representing a year-on-year growth of 114.86%. The net profit attributable to shareholders was 145 million CNY, showing a significant year-on-year increase of 1504.30% [2]. - The company has distributed a total of 417 million CNY in dividends since its A-share listing, with no dividends distributed in the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders of Hanyu Pharmaceutical reached 63,000, an increase of 9.95% compared to the previous period. The average number of circulating shares per person is 11,841, which is a decrease of 3.98% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fifth largest, holding 7.6817 million shares, which is a decrease of 386,400 shares compared to the previous period [3]. Market Activity - Hanyu Pharmaceutical has appeared on the "Dragon and Tiger List" once this year, with the most recent appearance on August 4, where it recorded a net purchase of 545 million CNY. The total purchases amounted to 882 million CNY, accounting for 18.83% of the total trading volume, while total sales were 337 million CNY, accounting for 7.20% [1].